Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 17/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 9/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6284918 | 1.00 | ADRB3 (0.49) | ADRB3ADRB1ADRB2ADRA1DADRA1A | |
| SCHEMBL6391912 | 1.00 | ADRB3 (0.49) | ADRB3ADRB1ADRB2ADRA1DADRA1A | |
| SCHEMBL6391905 | 1.00 | ADRB3 (0.49) | ADRB3ADRB1ADRB2ADRA1DADRA1A | |
| SCHEMBL6284036 | 0.92 | ADRB3 (0.51) | ADRB3ADRB1 | |
| SCHEMBL6284043 | 0.92 | ADRB3 (0.51) | ADRB3ADRB1 | |
| SCHEMBL6277637 | 0.91 | ADRB3 (0.49) | ADRB3ADRB1ADRB2 | |
| SCHEMBL6277639 | 0.91 | ADRB3 (0.49) | ADRB3ADRB1ADRB2 | |
| SCHEMBL6600472 | 0.89 | ADRB3 (0.62) | ADRB3ADRB1ADRB2 | |
| SCHEMBL6284175 | 0.89 | ADRB3 (0.52) | ADRB3ADRB1ADRB2 | |
| SCHEMBL6284190 | 0.89 | ADRB3 (0.52) | ADRB3ADRB1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050215594-A1 | 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-09-29 | — | — | US | disclosed |
| US-6919371-B2 | 2,6-substituted chroman derivatives useful as beta-3 adrenoreceptor agonists | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-07-19 | — | — | US | disclosed |
| US-6660752-B2 | Adrenergic blocking agents | BAYER PHARMACEUTICALS CORPORATION | 2003-12-09 | — | — | US | disclosed |
| US-20030078260-A1 | 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists | BAYER PHARMACEUTICALS CORPORATION | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215594-A1 | 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB1 3/4885ADRB2 2/4885 |
| US-20030078260-A1 | 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB1 3/4885ADRB2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.